US Stock Market Closed

Dashboard

Nymox Pharmaceutical Corp. (NYMX)

Current

- (-)

After Hours

Rating & Fair Value

Rating Premium lock
Fair Value Premium lock
Institutional Holdings

H

Financial Strength

S

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

About

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

CEO

Paul Averback

Employees

4

Industry

-

Sector

-

Headquarters

Nassau

Exchange

NASDAQ

Website

http://www.nymox.com

Summary Stats

Market Cap

40.7M

Revenue

0

Net Income

-11.6M

EPS

-$0.15

Price-to-Earnings

-2.94

Price-to-Book

-3394.32

Debt-to-Equity

-122.25

News

Analyst Ratings

Price targets projected by 1 analyst

High

$9.00

Average

$9.00

Low

$9.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Not Available

Actual

-$0.02 -

Consensus

-

Report Date

Year Ago

-0.04

Year Ago Change %

Up 50%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

Abbott Laboratories

ABT

Quest Diagnostics, Inc.

DGX

Johnson & Johnson

JNJ

Eli Lilly & Co.

LLY

Pfizer Inc.

PFE

Sophiris Bio Inc

SPHS

star Favorites